ba0001pp131 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013
Hadji Peyman
, Kauka Anette
, Bauer Thomas
, Ziller May
, Birkholz Katrin
, Baier Monika
, Muth Mathias
, Kann Peter
Introduction: Loss in bone mineral density may occur soon after initiation of adjuvant therapy for hormone-receptor-positive (HR+), breast cancer (BC) and correlates with changes in hormone levels. Adding zoledronic acid (ZOL) to adjuvant treatment for BC can preserve/improve bone mineral density and delay disease recurrence; however, effects of ZOL on endocrine hormone levels are currently unclear.Methods: Probone II assessed the course of endocrine hor...